Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Completed 11Terminated 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Other solid neoplasm 1Other 1

Conditions

Obesity 1Metabolic Syndrome 1Inflammation 1Hematopoietic and Lymphatic System Neoplasm 1Dyslipidemias 1

Interventions

pembrolizumab 223Cyclophosphamide 192Radiotherapy 183Nivolumab 181Carboplatin 153Cisplatin 114Paclitaxel 112Dexamethasone 110Radiosurgery 103Magnetic Resonance Spectroscopy 97Surveys and Questionnaires 90Ipilimumab 81Doxorubicin 79Lenalidomide 76Rituximab 75durvalumab 74atezolizumab 72Radiation 72fludarabine 68Standard of Care 68Gemcitabine 68venetoclax 67Specimen Handling 65Etoposide 64Capecitabine 64Bevacizumab 62Oxaliplatin 59Docetaxel 58Biopsy 58Radiotherapy, Intensity-Modulated 56

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Active not recruiting × OTHER × Bupropion × Clear all
NCT03996265 2026-01-15

Bupropion to Reduce Cancer Related Fatigue in Cancer Survivors

University of Rochester

Phase 3 Active not recruiting
422 enrolled
Other solid neoplasm

Hematopoietic and Lymphatic System Neoplasm

NCT05756764 2025-09-09

Anti-obesity Pharmacotherapy and Inflammation

Louisiana State University Health Sciences Center in New Orleans

Active not recruiting
30 enrolled
Other

Inflammation, Obesity, Metabolic Syndrome, Dyslipidemias

Data powered by HemOnc (CC BY 4.0) Colophon âš¡